Processa Pharmaceuticals Inc - Eight of 12 Evaluable Patients (66.7%) Had Progression-Free Survival (Pfs) Ranging From 5 to 11 Months
Processa Pharmaceuticals公司 - 12名可評估患者中的8名(66.7%)具有5至11個月不斷病情惡化的無進展生存期(PFS)
Processa Pharmaceuticals Inc - Eight of 12 Evaluable Patients (66.7%) Had Progression-Free Survival (Pfs) Ranging From 5 to 11 Months
Processa Pharmaceuticals公司 - 12名可評估患者中的8名(66.7%)具有5至11個月不斷病情惡化的無進展生存期(PFS)
譯文內容由第三人軟體翻譯。